The trial builds upon over ten years of collaborative research and paves the way for future multi-centre trials led by ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced ...

Monitor Epstein-Barr virus serology, development of infections during therapy. Oral forms are not interchangeable with other tacrolimus ext-rel products. Only physicians experienced in ...

Dermatitis. 2005;16(1):6-21. There has been a report of two patients with localized scleroderma treated with 0.1% topical tacrolimus ointment twice daily under occlusion. There was marked clinical ...

Overall, 6 out of 10 ciclosporin-treated patients and 5 out of 10 tacrolimus-treated patients maintained complete remission over the mean follow-up period of 23.0 ± 10.1 months after therapy ...

Tacrolimus 0.5mg, 1mg ... Monitor Epstein-Barr virus serology, development of infections during therapy. Risk of new onset diabetes after transplant (esp. Hispanic and black patients); monitor ...

The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg ... including breakthrough therapy ...

The first line therapy for DC and proctitis should primarily ... that may be potentially efficacious including medications like tacrolimus suppositories, and tacrolimus, ecabet sodium, Acetarsol ...

which were not controlled by the combination of anticonvulsants plus tacrolimus. The pathophysiological rationale underlying the use of a B-cell-depleting therapy, rituximab, was to suppress B ...